Phlow
Phlow Corp. is a U.S.-based pharmaceutical CDMO that develops and manufactures small molecule APIs for essential medicines using continuous flow chemistry, serving U.S. government agencies and pharmaceutical companies from operational cGMP facilities in Virginia.
- Company typePrivate
- Founded2020
- HeadquartersRichmond, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Phlow does
Phlow Corp. is a U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule active pharmaceutical ingredients (APIs) for essential medicines. Founded in 2020 and headquartered in Richmond, Virginia, the company operates two newly operational cGMP manufacturing facilities capable of producing APIs at both kilogram and metric-ton scales using both batch and continuous processes. Its core technology platform is built around continuous flow chemistry and modern manufacturing methods intended to improve quality, reliability, and environmental outcomes relative to traditional batch manufacturing. The company is a Delaware public benefit corporation with B Corporation certification and operates a wholly-owned subsidiary, MedPhlow, focused on novel essential medicine delivery solutions.
The company's revenue model is dual-track. The dominant track is U.S. government contracting, with cumulative awarded contracts exceeding $600 million spanning federal agencies including BARDA, the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), and FDA programs for medical countermeasures, essential medicines, and national preparedness initiatives. The secondary track is fee-for-service CDMO engagements with private pharmaceutical companies, including process development, analytical services, and commercial-scale API production. Phlow sells exclusively through direct enterprise engagement, not through traditional distribution channels. Notable commercial milestones include shipment of over 1.6 million vials of essential medicines to leading children's hospitals via the Children's Hospital Coalition, a flagship end-to-end domestic manufacturing collaboration with Fresenius Kabi for Epinephrine Injection, USP (announced February 2026), and selection for the first-ever FDA Commissioner's National Priority Voucher Pilot Program to domestically produce the ketamine API.
Phlow is augmenting its core manufacturing operations with an AI-driven chemistry platform developed in partnership with Enveda, which has generated nearly 20,000 unique reactions in three months and produced substantially more accurate yield-prediction models than those trained on public datasets. Additional program offerings include the cdmoX manufacturing services platform and SAPIR (Strategic Active Pharmaceutical Ingredient Reserve), a federal-aligned program designed to enhance domestic pharmaceutical supply chain resilience. Leadership was strengthened in 2025–2026 with the appointments of Tim M. Mayleben as Chairman of the Board (October 2025) and then Chief Executive Officer (May 2026), and Dawn Von Rohr as Chief Operating Officer (March 2026), both bringing extensive commercial pharmaceutical operating experience.
Phlow firmographics
Firmographics- Name
- Phlow
- Legal name
- Phlow Corporation
- Website
- https://phlow-usa.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Phlow Corp. is a U.S.-based pharmaceutical CDMO that develops and manufactures small molecule APIs for essential medicines using continuous flow chemistry, serving U.S. government agencies and pharmaceutical companies from operational cGMP facilities in Virginia.
- Ownership category
- akta.pro rank
Phlow industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Phlow is headquartered
LocationHeadquarters
- HQ city
- Richmond
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Phlow business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Government Contracts and CDMO Services: Phlow generates revenue through awarded government contracts exceeding $600 million for pharmaceutical manufacturing services, API production for essential medicines, and medical countermeasure development. Additionally provides fee-for-service CDMO offerings including process development, analytical services, and manufacturing for pharmaceutical companies.
- Private CDMO Services: Contract development and manufacturing organization services for private pharmaceutical companies, including advanced development and manufacturing solutions, process development, and commercial-scale API production.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Phlow product offering
Product offeringCore offering
Phlow is a U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule active pharmaceutical ingredients (APIs) from early-stage process development through commercial-scale production. The company operates two cGMP facilities (kilo-scale and metric ton-scale) in Virginia, supports pharmaceutical companies and U.S. government agencies with API manufacturing, and runs dedicated programs including cdmoX, SAPIR, and Government/NGO services.
Product overview
Phlow is a modern, U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) offering an integrated suite of small molecule API development and manufacturing services. The core offering comprises Process Research & Development and Analytical Laboratories for early-stage development, a Kilo-Scale cGMP Facility for flexible small-batch production supporting preclinical and clinical stages, and a Metric Ton-Scale cGMP Facility for high-volume commercial manufacturing. These manufacturing capabilities are powered by advanced technologies including continuous flow chemistry. Supporting programs include the cdmoX program for customer engagements, the SAPIR (Strategic Active Pharmaceutical Ingredient Reserve) for government and national preparedness initiatives, and a Government/NGO services division for medical countermeasures. Recent additions include an AI-Driven Chemistry Platform developed in partnership with Enveda for accelerated process development, and domestic epinephrine API production as part of an end-to-end collaboration with Fresenius Kabi. The company operates from facilities in Richmond and Petersburg, Virginia, all within the Eastern U.S. timezone.
Differentiator
Problem solved
Functional benefit
Products and services
- Small Molecule API Development and Manufacturing End-to-end contract development and manufacturing of small molecule Active Pharmaceutical Ingredients (APIs), from early-stage process development and analytical support through kilo-scale and metric ton-scale cGMP commercial production, for pharmaceutical company customers.
- cdmoX Program A dedicated CDMO program supporting customer drug programs through advanced development and manufacturing solutions, including continuous flow chemistry, aimed at reducing drug shortages and boosting U.S. pharmaceutical independence for pharmaceutical company customers.
- SAPIR (Strategic Active Pharmaceutical Ingredient Reserve) A strategic reserve program that enhances U.S. domestic pharmaceutical supply chain resilience and drug supply security by maintaining a reserve of strategically important active pharmaceutical ingredients for U.S. government and national preparedness customers.
- Government/NGO Pharmaceutical Services Pharmaceutical development and manufacturing services for U.S. government agencies and NGOs, including medical countermeasures for chemical and biological threats, pediatric essential medicines, and national preparedness initiatives.
- Epinephrine Injection API Production Domestic manufacturing of the active pharmaceutical ingredient for Epinephrine Injection, USP, delivered as part of an end-to-end collaboration with Fresenius Kabi that handles formulation and finished dose production for U.S. hospitals and clinics.
Quantifiable outcome
- Generated nearly 20,000 unique chemical reactions in 3 months, compressing development timelines from years to months
- +2 more outcomes
Companies that use Phlow
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Phlow technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Phlow partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered major, flagship and core.
- Virginia Innovation Partnership Corporation (VIPC)majorCollaboration supporting Virginia's biopharma ecosystem development. Phlow is part of the collaborative infrastructure including the Medicines for All Institute at Virginia Commonwealth University, Civica Rx, and the Alliance for Building Better Medicine, collectively creating a resilient regional biopharmaceutical ecosystem and reshoring essential medicine manufacturing.
- Fresenius KabiflagshipFirst-ever end-to-end domestic manufacturing collaboration for Epinephrine Injection, USP. Phlow produces the active pharmaceutical ingredient (API) while Fresenius Kabi handles formulation and finished dose production for hospitals and clinics. Addresses chronic shortage risk for this essential medicine, with domestically manufactured product expected to be available to U.S. hospitals by 2027. Designed to be scalable to other essential medicines.
- EnvedacoreAI-driven chemistry partnership to accelerate domestic pharmaceutical development and transform drug substance manufacturing. Joint pilot program demonstrated that AI-driven chemistry can significantly compress development timelines from years to months. Generated nearly 20,000 unique reactions in three months, creating one of the largest high-quality chemical datasets in the field. AI models trained on internally generated data produced substantially more accurate yield predictions.
- U.S. Food and Drug Administration (FDA)majorSelected for the first-ever FDA Commissioner's National Priority Voucher Pilot Program to produce the active pharmaceutical ingredient for ketamine domestically. Initiative aims to strengthen U.S. pharmaceutical supply chain and address multi-year shortage of ketamine, leveraging vouchers to accelerate FDA review processes for domestic manufacturing projects.
- Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND)majorPartnership to develop medical countermeasure drug products that support the joint force and its allies in counteracting chemical and biological threats. Part of Phlow's government contract work supporting national preparedness.
- Children's Hospital CoalitioncoreFirst-of-its-kind initiative to combat pediatric drug shortages. Phlow has shipped over 1.6 million vials of essential medicines to leading children's hospitals across the country through this coalition.
- U.S. Government (Federal Contracts)flagshipFoundational government partnerships including federal contracts exceeding $600 million supporting domestic pharmaceutical manufacturing, essential medicine production, and national preparedness programs. Includes BARDA and other health security contracts.
Scale indicators5 records
Recent moves7 records
Expansion highlights8 records
Phlow competitors and assessment
Company assessmentDirect peers
- Cambrex: Cambrex is a leading small-molecule API CDMO offering process development, scale-up, and commercial manufacturing for pharmaceutical customers. Directly comparable to Phlow across small-molecule API development, cGMP manufacturing at multiple scales, and target customer base of pharma companies and government programs.
- Curia Global: Curia Global is a contract development and manufacturing organization with deep small-molecule API capabilities across process R&D, analytical services, and commercial-scale manufacturing. Highly comparable to Phlow, including overlap via Phlow COO Dawn Von Rohr's prior SVP role leading global API operations at Curia.
- Hovione: Hovione is a privately-held CDMO specializing in small-molecule API development and manufacturing, including advanced particle engineering and continuous manufacturing. Comparable to Phlow in focus on small-molecule APIs, advanced manufacturing technologies, and integrated development-to-commercial services for pharmaceutical customers.
- Piramal Pharma Solutions: Piramal Pharma Solutions is a global CDMO offering API development and manufacturing across multiple scales, including small molecules. Directly comparable to Phlow on small-molecule API CDMO services and customer overlap with pharmaceutical companies seeking contract manufacturing capacity.
- AGC Pharma Chemicals: AGC Pharma Chemicals (formerly AGC Asahi Glass) is a global CDMO providing small-molecule API development and manufacturing services, including highly potent APIs. Comparable to Phlow in small-molecule API focus, multi-scale cGMP manufacturing, and pharmaceutical customer base.
- Veranova: Veranova (formerly the Health division of Johnson Matthey) is a global CDMO specializing in small-molecule API development and manufacturing, including complex APIs. Directly comparable to Phlow on small-molecule API focus and integrated development-to-commercial manufacturing services.
Broad incumbents
- Patheon (Thermo Fisher Scientific): Patheon, now part of Thermo Fisher Scientific's pharma services division, is one of the largest global CDMOs offering small-molecule API and drug product manufacturing. Serves as a broad incumbent with overlapping capabilities to Phlow but a far larger scale, broader service portfolio, and global footprint.
Emerging players
- Sai Life Sciences: Sai Life Sciences is an India-headquartered CDMO providing small-molecule API discovery, development, and manufacturing services. Comparable to Phlow on small-molecule API CDMO services, though Sai Life Sciences operates primarily from India-based facilities serving global pharmaceutical customers rather than a U.S.-domestic focus.
- Antheia: Antheia is a U.S.-based pharmaceutical ingredient manufacturer using synthetic biology and advanced manufacturing to transform essential medicine supply chains. Directly comparable to Phlow as a U.S.-focused domestic API manufacturing partner; Phlow has an active technology partnership with Antheia to bolster U.S. pharmaceutical supply chains.
- Civica Rx: Civica Rx is a non-profit generic drug company focused on addressing drug shortages and reducing reliance on overseas manufacturing through U.S.-based production. Part of Phlow's Virginia biopharma ecosystem collaboration alongside the Medicines for All Institute at VCU, addressing overlapping domestic essential-medicine supply challenges.
Market position
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Phlow social profiles
Digital presencePhlow compliance and trust
Trust signalCompliance2 records
Phlow financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phlow leadership team
Management profileNumber of profiles
Profiles4 records
Phlow subsidiaries and ownership
Company hierarchySubsidiaries1 record
Phlow funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phlow M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phlow
What does Phlow do?
Phlow is a U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule active pharmaceutical ingredients (APIs) from early-stage process development through commercial-scale production. The company operates two cGMP facilities (kilo-scale and metric ton-scale) in Virginia, supports pharmaceutical companies and U.S. government agencies with API manufacturing, and runs dedicated programs including cdmoX, SAPIR, and Government/NGO services.
Is Phlow a public or private company?
Phlow is a private company. It is classified as venture growth investor backed and is currently operating.
When was Phlow founded?
Phlow was founded in 2020. It employs 51 to 100 people.
Where is Phlow based?
Phlow is headquartered in Richmond, United States, in the North America region.
How does Phlow make money?
Two revenue lines are on record. Government Contracts and CDMO Services are the primary driver. The others are private CDMO Services.
Who are Phlow's main competitors?
Direct peers on record are Cambrex, Curia Global, Hovione, Piramal Pharma Solutions, AGC Pharma Chemicals and Veranova. Patheon (Thermo Fisher Scientific) is listed as a broad incumbent. Emerging players are Sai Life Sciences, Antheia and Civica Rx.
Does Phlow have an API?
No public API is recorded for Phlow.
What industry is Phlow in?
Phlow's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.